vs

Side-by-side financial comparison of Empire State Realty Trust, Inc. (ESRT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $190.3M, roughly 1.2× Empire State Realty Trust, Inc.). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs 1.6%, a 17.8% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 5.7%). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 0.2%).

Empire State Realty Trust is a leading real estate investment trust that owns, manages, and operates a portfolio of premium commercial, residential, and retail properties primarily in the New York City metropolitan area, including the iconic Empire State Building. It serves corporate tenants, retail partners, and residential occupants, focusing on sustainable property operations and long-term asset value growth.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ESRT vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.2× larger
ORGO
$225.6M
$190.3M
ESRT
Growing faster (revenue YoY)
ORGO
ORGO
+72.4% gap
ORGO
78.1%
5.7%
ESRT
Higher net margin
ORGO
ORGO
17.8% more per $
ORGO
19.4%
1.6%
ESRT
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
0.2%
ESRT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ESRT
ESRT
ORGO
ORGO
Revenue
$190.3M
$225.6M
Net Profit
$3.0M
$43.7M
Gross Margin
Operating Margin
15.5%
28.1%
Net Margin
1.6%
19.4%
Revenue YoY
5.7%
78.1%
Net Profit YoY
-73.7%
469.5%
EPS (diluted)
$0.20
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESRT
ESRT
ORGO
ORGO
Q1 26
$190.3M
Q4 25
$199.2M
$225.6M
Q3 25
$197.7M
$150.9M
Q2 25
$191.3M
$101.0M
Q1 25
$180.1M
$86.7M
Q4 24
$197.6M
$126.7M
Q3 24
$199.6M
$115.2M
Q2 24
$189.5M
$130.2M
Net Profit
ESRT
ESRT
ORGO
ORGO
Q1 26
$3.0M
Q4 25
$32.2M
$43.7M
Q3 25
$13.6M
$21.6M
Q2 25
$11.4M
$-9.4M
Q1 25
$15.8M
$-18.8M
Q4 24
$18.8M
$7.7M
Q3 24
$22.8M
$12.3M
Q2 24
$28.6M
$-17.0M
Gross Margin
ESRT
ESRT
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ESRT
ESRT
ORGO
ORGO
Q1 26
15.5%
Q4 25
17.8%
28.1%
Q3 25
19.9%
13.7%
Q2 25
18.4%
-12.5%
Q1 25
14.3%
-30.9%
Q4 24
21.7%
8.1%
Q3 24
22.7%
5.4%
Q2 24
20.8%
-10.7%
Net Margin
ESRT
ESRT
ORGO
ORGO
Q1 26
1.6%
Q4 25
16.1%
19.4%
Q3 25
6.9%
14.3%
Q2 25
6.0%
-9.3%
Q1 25
8.8%
-21.7%
Q4 24
9.5%
6.1%
Q3 24
11.4%
10.7%
Q2 24
15.1%
-13.1%
EPS (diluted)
ESRT
ESRT
ORGO
ORGO
Q1 26
$0.20
Q4 25
$0.11
$0.31
Q3 25
$0.05
$0.11
Q2 25
$0.04
$-0.10
Q1 25
$0.05
$-0.17
Q4 24
$0.07
$0.05
Q3 24
$0.08
$0.09
Q2 24
$0.10
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESRT
ESRT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$68.8M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.8B
$300.1M
Total Assets
$4.4B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESRT
ESRT
ORGO
ORGO
Q1 26
$68.8M
Q4 25
$132.7M
$93.7M
Q3 25
$154.1M
$63.7M
Q2 25
$94.6M
$73.1M
Q1 25
$187.8M
$110.0M
Q4 24
$385.5M
$135.6M
Q3 24
$421.9M
$94.3M
Q2 24
$535.5M
$89.9M
Total Debt
ESRT
ESRT
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ESRT
ESRT
ORGO
ORGO
Q1 26
$1.8B
Q4 25
$1.1B
$300.1M
Q3 25
$1.0B
$255.1M
Q2 25
$1.0B
$233.2M
Q1 25
$1.0B
$242.9M
Q4 24
$1.0B
$262.9M
Q3 24
$1.0B
$278.5M
Q2 24
$1.0B
$263.5M
Total Assets
ESRT
ESRT
ORGO
ORGO
Q1 26
$4.4B
Q4 25
$4.5B
$598.7M
Q3 25
$4.1B
$509.8M
Q2 25
$4.1B
$461.1M
Q1 25
$4.1B
$467.4M
Q4 24
$4.5B
$497.9M
Q3 24
$4.4B
$446.3M
Q2 24
$4.4B
$443.2M
Debt / Equity
ESRT
ESRT
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESRT
ESRT
ORGO
ORGO
Operating Cash FlowLast quarter
$39.4M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
10.0%
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESRT
ESRT
ORGO
ORGO
Q1 26
Q4 25
$249.1M
$39.4M
Q3 25
$105.3M
$3.1M
Q2 25
$26.7M
$-32.9M
Q1 25
$83.1M
$-19.9M
Q4 24
$260.9M
$10.9M
Q3 24
$102.8M
$8.7M
Q2 24
$37.1M
$4.7M
Free Cash Flow
ESRT
ESRT
ORGO
ORGO
Q1 26
Q4 25
$50.6M
$34.8M
Q3 25
$72.8M
$844.0K
Q2 25
$-55.1M
$-36.5M
Q1 25
$41.1M
$-23.6M
Q4 24
$88.0M
$7.6M
Q3 24
$-65.1M
$6.1M
Q2 24
$19.5M
$2.9M
FCF Margin
ESRT
ESRT
ORGO
ORGO
Q1 26
Q4 25
25.4%
15.4%
Q3 25
36.8%
0.6%
Q2 25
-28.8%
-36.1%
Q1 25
22.8%
-27.2%
Q4 24
44.5%
6.0%
Q3 24
-32.6%
5.3%
Q2 24
10.3%
2.2%
Capex Intensity
ESRT
ESRT
ORGO
ORGO
Q1 26
10.0%
Q4 25
99.6%
2.1%
Q3 25
16.5%
1.5%
Q2 25
42.8%
3.6%
Q1 25
23.4%
4.2%
Q4 24
87.5%
2.7%
Q3 24
84.1%
2.2%
Q2 24
9.3%
1.4%
Cash Conversion
ESRT
ESRT
ORGO
ORGO
Q1 26
Q4 25
7.74×
0.90×
Q3 25
7.72×
0.14×
Q2 25
2.35×
Q1 25
5.27×
Q4 24
13.88×
1.43×
Q3 24
4.51×
0.71×
Q2 24
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESRT
ESRT

Rental revenue (1)$166.1M87%
Observatory revenue$18.5M10%
Other revenue and fees$4.1M2%
Lease termination fees$1.4M1%
Third-party management and other fees$277.0K0%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons